The group’s principal activity is to develop oral controlled-release products. The group’s products include INT0001/2004, INT0003/2005, INT0004/2006, INT0005/2005, INT0006/2005, INT10/2006 and INT0007/2006. In April 2006, the group acquired IntelGenx Technologies Corp. The group operates from the United States. The revenue of the group in the year 2006, were $265,901.
